MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.8 EUR | -2.01% |
|
-1.76% | +11.75% |
| May. 08 | Mickey Mouse on Wall Street |  |
| Apr. 15 | MaaT Pharma: positive data in graft-versus-host disease | CF |
| Sales 2024 * | 4M 4.31M | Sales 2025 * | 4.4M 4.74M | Capitalization | 108M 117M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -31.21M | Net income 2025 * | -29M -31.21M | EV / Sales 2024 * | 24.9 x |
| Net cash position 2024 * | 8.6M 9.26M | Net cash position 2025 * | 7.9M 8.5M | EV / Sales 2025 * | 22.8 x |
| P/E ratio 2024 * |
-3.34
x | P/E ratio 2025 * |
-3.27
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaaT Pharma
More press releases
| 1 day | -2.01% | ||
| 1 week | -1.76% | ||
| Current month | -2.50% | ||
| 1 month | -16.49% | ||
| 3 months | -4.88% | ||
| 6 months | +20.37% | ||
| Current year | +11.75% |
1 week
7.80
8.00
1 month
7.809.44
Current year
6.409.90
1 year
4.509.90
3 years
4.5014.40
5 years
4.5014.40
10 years
4.5014.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
FOU | Founder | - | 13-12-31 |
Siân Crouzet
DFI | Director of Finance/CFO | - | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 13-12-31 | |
Claude Bertrand
BRD | Director/Board Member | 62 | 20-07-15 |
Muriel Prudent
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 7.8 | -2.01% | 1,338 |
| 24-06-07 | 7.96 | +1.27% | 1,736 |
| 24-06-06 | 7.86 | -0.51% | 863 |
| 24-06-05 | 7.9 | 0.00% | 328 |
| 24-06-04 | 7.9 | -0.50% | 1,285 |
Real-time Euronext Paris, June 10, 2024 at 11:18 am EDT
More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-06-10
- Portzamparc Mid & Small Caps Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.8
EUR
Average target price
14.6
EUR
Spread / Average Target
+87.18%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.75% | 120M | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 24.21B | |
| +2.07% | 22.78B | |
| -10.79% | 17.96B | |
| -41.74% | 16.43B | |
| -13.47% | 16.37B | |
| +2.23% | 13.58B | |
| +27.13% | 11.66B |
- Stock Market
- Equities
- MAAT Stock
